Research that is free to access for all investors. Companies commission these providers to write research about them.
Brokers who write research on their corporate clients and make it available through our main bundle offering.
Research that is paid for directly by asset managers. Only accessible to institutional investors permissioned for access.
Event in Progress:
Discover the latest content that has just been published on Research Tree
RELX released organic sales growth figures in line with expectations, confirming the strong momentum seen in H1 23. The guidance was reiterated despite the potential macro headwinds.
Companies: RELX PLC
AlphaValue
The markets are cheering the solid results reported by RELX in terms of revenue and profitability growth across all divisions as well as the announcement of an increase in its interim dividend. The guidance was reaffirmed for the year with the performance expected to be above the historical trend.
RELX’s results for FY22 came in above expectations. The continued growth in earnings as well as the EPS, dividend and share buyback program of £800m are being rewarded by investors who are boosting the share price to a new high.
This is our first report on Relx, a well-known provider of information-based analytics and decision tools for professionals as well as businesses. In the first half of 2022, the company generated solid financial results, with revenue growing by 13% at constant exchange rates. Business Services, accounting for around 45% of the division's sales, produced a significant revenue increase. Their digital identification solutions for fraud and identity saw extremely significant growth, with ThreatMetri
Baptista Research
The 9-months 2022 trading statement was in line, confirming organic revenue growth above historical trends for the second year. The group reiterated its FY22e guidance as “momentum remains strong”, which is very reassuring in light of the current macro environment.
RELX reported excellent H1 22 results in light of the current macro environment. The management said that the momentum remains strong entering H2 22 and that it continues to expect the FY22e performance to be above the historical trend.
RELX released a reassuring trading statement ahead of its April 2022 AGM to confirm its FY22e outlook, as all business lines performed well in Q1 22. Not to look a gift horse in the mouth, but perhaps a little more detail about Exhibitions would have been appreciated…
RELX’s FY21 top- and bottom-line trends fall short of expectations, dampening investor sentiment. The better-than-anticipated adjusted EPS and dividend, as well as the long-awaited return of the share buy-back programme, were not enough to support the share price…
RELX shares reached a new all-time high this morning following the publication of the group’s 9-month trading update. Investors welcomed the – long-awaited – bounce back in Exhibitions as well as the improved FY21e guidance.
RELX raised its FY21e guidance on the back of very encouraging H1 21 results. Its three major divisions delivered a sound performance, similar to pre-COVID-19 trends, which offset the continued weakness in Exhibitions.
RELX released a trading statement ahead of its April 2021 AGM to confirm its FY21e outlook as most of the business performed well in Q1 21. The timing and pace of recovery in Exhibitions remains uncertain.
The FY20 results are both satisfactory and in line. More than 4/5ths of the business are continuing to hold up well, with uncertainty remaining on Exhibitions. The FY dividend’s increase by 3% is good news. Positive stance maintained after allowing for negative tweaks on the Exhibitions outlook.
RELX issued a fairly sound 9 month trading statement despite the Exhibitions division remaining highly impacted by the current pandemic. More than 4/5 of the business are continuing to hold up well, which we consider a positive. The FY20e outlook is unchanged for the three largest divisions while Exhibitions continue to suffer. Some downgrade adjustments are expected to our forecasts, mostly due to Exhibitions, but we intend to reiterate a positive recommendation on the stock.
RELX’s H1 20 results are clearly not good, impacted by COVID-19 as expected. Both revenues and adjusted OP were below our estimates and the street’s as Exhibitions were significantly hurt. Positively, all other businesses continued to deliver and are continuing to hold up well. The flat interim dividend, contrary to market fears, was also a positive. Our earnings will be downgraded. High volatility expected going forward for the share price but we remain confident in the group’s long-term strate
RELX just released a trading statement ahead of is 23 April 2020 AGM to inform that it has suspended both its FY20e guidance and share buy-back due to the uncertainties related to COVID-19.
Research Tree provides access to ongoing research coverage, media content and regulatory news on RELX PLC. We currently have 0 research reports from 7 professional analysts.
Post further analysis of the FY 2023 results on 9 April 2024, we are establishing FY 2025 forecasts, as well as modifying our forecast adjusted net profit/EPS figures for 2024 and 2025 to reflect the accounting of the deferred tax asset. Our 2025 forecast calls for 9% growth in customer revenues, stable other operating income (largely R&D tax credits) vs 2024, EBITDA margins going back to the 23% level (after a slight contraction in 2024 to reflect 3 facilities being run in parallel for part of
Companies: hVIVO plc
Cavendish
Companies: MPE TRI VNET BVXP HVO
Braemar’s FY24 trading update was in line with expectations, with revenues of c £150m and underlying operating profit of c £18m. Underlying operations continue to expand and diversify and the company remains well-positioned to drive its future growth strategy. The trading outlook is promising and Braemar should be able to leverage its strong balance sheet in pursuit of strategic growth. We have maintained our underlying estimates for FY24 and FY25, but edge down the valuation based on the lower
Companies: Braemar PLC
Edison
Elixirr offers investors exposure to the long-term growth trends in the global Consulting market (including digitisation and the ongoing technology revolution, demand for innovation, efficiency and specialised expertise) all turbo charged by the group’s ‘challenger’ strategy driving market share gain from a low base. FY 2023 results showed the power of Elixirr’s differentiated model with revenue up +20% and adj. EPS up +22% in a market subdued by global uncertainty. With net cash of £18m, a posi
Companies: Elixirr International Plc
We reveal the winners of our investment trust ratings for 2024... Our ratings seek to reward closed-ended funds which deliver attractive and persistent performance characteristics in three categories which we think match up to broad goals investors usually have: long-term growth, income and growth, and high current income. This includes strong performance versus a fund’s underlying market, as well as attractive risk characteristics which we think suggests they could continue to be premium optio
Companies: DIG JCGI SCP MUT SOI JEMI MRC AIE JGGI CCJI
Kepler | Trust Intelligence
Having completed its five-year growth plan a year ahead of schedule, despite the intervening pandemic, GlobalData has now set out its ambitions for the next three years. These build on the group’s strengths in platform and proprietary data across its three segments in healthcare (36% of FY23e revenue), consumer (36%) and tech (28%). M&A is a key element, with the group’s financial strength significantly bolstered by the deal with Inflexion in December, where Inflexion took a 40% stake in GlobalD
Companies: GlobalData Plc
Companies: AURA OMI AAL KAV POW BMN EST SVML
SP Angel
As pre-announced, Avacta has presented the results of the 3-weekly P1 Arm 1 study of its AVA6000 lead clinical asset, based on the pre|CISION™ drug development platform at the American Association for Cancer Research's annual general meeting. The update does not cover progress on the ongoing 2-weekly dosing study which is underway, and Avacta confirmed current guidance on timing including being on track to begin the dose expansion study in 2H24. There are compelling updates on the progress repor
Companies: Avacta Group PLC
Capital Access Group
What you need to know: • BQE reported Q4 & 2023 financial results yesterday that came in largely ahead of our expectations on revenue. • Proportional revenue was $5.4M compared to our estimate of $4.2M and adjusted EBITDA was $0.5M compared to our estimate of $0.6M. • BQE remains well positioned for another record year in 2024, we are expecting 8% revenue growth and 36% EBITDA growth. • We are increasing our target to $71/share based on 11.0x 2025E EBITDA. BQE Water (BQE:TSXV, BTQNF:OTC) repor
Companies: BQE Water Inc
Atrium Research
Braemar’s interim results indicate the strong trading of FY23 has continued during H1/24 and in-line with expectations, benefiting from the focus on shipbroking activities and the increased breadth, depth, and scale of shipbroking operations. Braemar’s investments (acquisition of Southport Marine) and new teams have delivered a 7.9% increase in revenue to £74.9m for H1/24. Whilst robust Tanker freight rates have continued despite geopolitical challenges and OPEC cuts, Dry Cargo freight rates fel
CCJI is an attractive ‘buy and hold’ strategy…
Companies: CC Japan Income And Growth Trust
CCJI leads the performance tables in Japan over one, three and five years…
Companies: BBY BYG FOUR SRP CTEC IDS SUPR DOM BOO
Liberum
Avacta reported revenue for the interim period to the end June of £11.9m, more than doubled YoY, reflecting the growth in the contribution from the Diagnostics Division, including an initial contribution from the Coris acquisition completed in June. However, the main driver to the company's share price performance remains progress in the clinical trials of the AVA6000 compound where the company recently announced the successful completion of dosing in cohort 6 in the Phase 1A trial and a propose
Companies: ITV RR/ KWS JD/ SENX
Shore Capital
Share: